Evidence map›Paper›PMID 17032712›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2007

An age-related decrease in creatinine clearance is associated with an increase in number of falls in untreated women but not in women receiving calcitriol treatment.

J Christopher Gallagher, Prema B Rapuri, Lynette M Smith

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 8 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 8 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019
    Guideline
  4. Pooled it
  5. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013
    Guideline
  6. Interventions for preventing falls in older people living in the community.The Cochrane database of systematic reviews · 2012
    Pooled it
  7. Vitamin D-related changes in physical performance: a systematic review.The journal of nutrition, health & aging · 2009
    Pooled it
  8. European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2008
    Guideline
  9. Trial
  10. Article
  11. Review
  12. Article
  13. Vitamin D: Musculoskeletal health.Reviews in endocrine & metabolic disorders · 2017
    Review
  14. Review
  15. Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2014
    Review
  16. Article
  17. Article
  18. Fracture risk assessment in patients with chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012
    Review
  19. Independent from muscle power and balance performance, a creatinine clearance below 65 ml/min is a significant and independent risk factor for falls and fall-related fractures in elderly men and women diagnosed with osteoporosis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2010
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

J Christopher GallagherBone Metabolism Unit, Creighton University Medical Center, School of Medicine, 601 North 30th Street, Room 6718, Omaha, Nebraska 68131, USA. jcg@creighton.edu
Prema B Rapuri
Lynette M Smith
CHI Health Creighton University Medical Center - Bergan Mercy · USUniversity of Nebraska Medical Center · US

Funding

PATHOPHYSIOLOGY OF SENILE TYPE 11 OSTEOPOROSISR01AG010358 · NIA · CREIGHTON UNIVERSITY · PI GALLAGHER, JOHN CHRISTOPHER · 1991 to 1995
–
TREATMENT FOR OSTEOPOROSIS OF THE HIP-SUPPLEMENT AG10373U01AG010373 · NIA · CREIGHTON UNIVERSITY · PI GALLAGHER, JOHN CHRISTOPHER · 1991 to 1998
–
NIA NIH HHS R01-AG10358NIA NIH HHS U01 AG010373-08NIA NIH HHS U01-AG10373
6 · The paper itself

Abstract

contextDecreased calcitriol production due to impaired renal function may be a significant risk factor for falls in normal aging population.

objectiveThe objective of the study was to examine the association between creatinine clearance (CrCl) and the incidence of falls and fallers in groups treated with placebo, calcitriol, estrogen therapy (ET)/estrogen + progestin therapy (HT), and calcitriol + ET/HT.

designThis was a 3-yr, double-blind, placebo-controlled study designed to test the efficacy of calcitriol and ET/HT on bone loss and falls with analysis by intention to treat and post hoc.

settingThe study was conducted at an academic outpatient center.

participantsFour hundred eighty-nine normal elderly women aged 65-77 yr; 415 women completed the study.

interventionSubjects were randomized to placebo, calcitriol 0.25 mug twice a day, ET daily (conjugated equine estrogens 0.625 mg), HT (conjugated equine estrogen 0.625 mg + medroxyprogesterone acetate 2.5 mg) and calcitriol + ET/HT.

main outcome measuresCumulative number of falls and fallers were compared between groups with 24-h urine CrCl less than 60 and 60 ml/min or greater.

resultsCalcitriol treatment decreased the number of fallers and falls. Low CrCl less than 60 ml/min was a predictor of the number of falls per person but not fallers in the placebo group (P = 0.007). In the low CrCl group (<60 ml/min), the rate of falls decreased on calcitriol by 53% [95% confidence interval (CI) -71% to -22%; P = 0.003], calcitriol + ET/HT by 61% (95% CI -76% to -37%; P = 0.001), and ET/HT by 25% (95% CI: -55% to +24%; not significant). Calcitriol reduced the rate of falls by 30% (95% CI -49% to -4%; P = 0.027) in the CrCl 60 ml/min or greater group.

conclusionCalcitriol treatment decreases falls in all subjects but especially in elderly women with decreased renal function (<60 ml/min) and frequent fallers.

Indexed as

Accidental FallsAgedAge FactorsCalcitriolCreatinineDouble-Blind MethodFemaleHumansMetabolic Clearance RateCalcitriolCreatinine

Identifiers

PMID17032712
PMCPMC1892155
OpenAlexW2152551407

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.